2024年12月23日 · Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens, such as viruses like SARS-CoV-2. The …

REGEN‑COV remains authorized for the treatment of mild-to-moderate COVID‑19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) with positive results of …

2024年12月17日 · Regen-Cov is usually given as only one dose as soon as possible after you are exposed to or test positive for COVID-19, or within 10 days after the start of symptoms. You …

Regen-Cov package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

REGEN-COV is investigational because it is still being studied. There is limited information known about the safety and effectiveness of using REGEN-COV to treat people with COVID-19 or to...

2022年1月22日 · The FDA authorized REGEN-COV for the treatment of mild-to-moderate COVID-19 in people aged 12 years and older who are at high risk of developing severe COVID-19. …

2021年9月29日 · In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

2024年4月29日 · Regen-Cov (casirivimab and imdevimab) is a combination of antibodies used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients …

As of January 24, 2022, due to the high frequency of the Omicron variant, REGEN-COV is not currently authorized for use in any U.S. region because of markedly reduced activity against the...

Given the high frequency of circulating SARS-CoV-2 variants that are non-susceptible to REGEN-COV® (casirivimab and imdevimab), REGEN-COV is not currently authorized in any U.S. …